Active Ingredient History
Clostridium butyricum is a strictly anaerobic endospore-forming Gram-positive butyric acid–producing bacillus subsisting by means of fermentation using an intracellularly accumulated amylopectin-like α-polyglucan (granulose) as a substrate. It is uncommonly reported as a human pathogen and is widely used as a probiotic in Japan, Korea, and China. C. butyricum is a soil inhabitant in various parts of the world, has been cultured from the stool of healthy children and adults, and is common in soured milk and cheeses. The connection with dairy products is shown by the name, the butyr- in butyricum reflects the relevance of butyric acid in the bacteria's metabolism and the connection with Latin butyrum and Greek βούτυρον, with word roots pertaining to butter and cheese. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Renal Cell (Phase 1)
Cardiovascular Diseases (Phase 4)
Clostridium Infections (Phase 2)
Colonic Neoplasms (Phase 2)
Colostomy (Phase 2)
Constipation (Phase 4)
Depression (Phase 4)
Dyspepsia (Phase 4)
Gastritis (Phase 4)
Helicobacter pylori (Phase 4)
Ileostomy (Early Phase 1)
Infections (Early Phase 1)
Irritable Bowel Syndrome (Phase 4)
Liver Cirrhosis (Phase 3)
Lymphoma (Phase 1)
Microbiota ()
Peptic Ulcer (Phase 4)
Rectal Neoplasms (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
